摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-dimethylcyclopent-2-en-5-olone | 25412-58-2

中文名称
——
中文别名
——
英文名称
3,5-dimethylcyclopent-2-en-5-olone
英文别名
3,5-Dimethyl-5-hydroxy-cyclopent-2-en-1-on;5-Hydroxy-3,5-dimethylcyclopent-2-enon;5-hydroxy-3,5-dimethylcyclopent-2-en-1-one
3,5-dimethylcyclopent-2-en-5-olone化学式
CAS
25412-58-2
化学式
C7H10O2
mdl
——
分子量
126.155
InChiKey
QGWWSJAFEUTZMS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为产物:
    参考文献:
    名称:
    αβ-不饱和1,2-二酮光环化的2-羟基环戊烯酮衍生物:建议的三重态双自由基中间体
    摘要:
    研究了5-甲基己-4-烯-2,3-二酮和1-(邻烷基苯基)丙烷-1,2-二酮的光环化成羟基环戊烯酮衍生物。鉴于观察到的反应的立体化学偏好,建议最初的H提取导致双自由基,该双自由基光环化为激发的三重态,而不导致光烯醇为中间体。根据目前的工作讨论了所报道的某些邻烷基乙酰基和苯甲酮的光烯醇化,并且根据苯并环丁烯醇中间体的热开放性对其进行了合理化。
    DOI:
    10.1039/j39700001193
点击查看最新优质反应信息

文献信息

  • Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence
    申请人:Gottesdiener Keith M.
    公开号:US20090270406A1
    公开(公告)日:2009-10-29
    This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof. In another aspect, this invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof.
    这项发明涉及用于治疗尿频、尿急和尿失禁的组合物,包括(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺及其药学上可接受的盐。另一方面,这项发明涉及用于尿频、尿急和尿失禁的联合疗法,其中一种活性药物是(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺及其药学上可接受的盐。
  • Novel intermediates for the preparation of .alpha.-hydroxycarbonyl
    申请人:Givaudan Corporation
    公开号:US04428886A1
    公开(公告)日:1984-01-31
    The instant invention provides a new and improved method of preparing .alpha.-hydroxycarbonyl compounds, particularly substituted cyclopent-2-en-2-ol-1-ones and substituted 3-hydroxy-2(5H)-furanones. The novel sequence involves a number of novel intermediates including substituted 2-cyanocyclopentanones, substituted 2-cyano-2-hydroxycyclopentanones, and 2-cyano-2-hydroxyvalero-.gamma.-lactones.
    本发明提供了一种新的和改进的制备α-羟基羰基化合物的方法,特别是取代的环戊-2-烯-2-醇-1-酮和取代的3-羟基-2(5H)-呋喃酮。这种新颖的序列涉及到许多新颖的中间体,包括取代的2-氰基环戊酮,取代的2-氰基-2-羟基环戊酮和2-氰基-2-羟基戊二酸-γ-内酯。
  • Process for the preparation of alpha-hydroxycarbonyl compounds
    申请人:Givaudan Corporation
    公开号:US04318855A1
    公开(公告)日:1982-03-09
    The instant invention provides a new and improved method of preparing .alpha.-hydroxycarbonyl compounds, particulary substituted cyclopent-2-en-2-ol-1-ones and substituted 3-hydroxy-2(5H)-furanones. The novel sequence involves a number of novel intermediates including substituted 2-cyanocyclopentanones, substituted 2-cyano-2-hydroxycyclopentanones, and 2-cyano-2-hydroxyvalero-.gamma.-lactones.
    本发明提供了一种新的、改进的制备α-羟基羰基化合物的方法,特别是取代的环戊-2-烯-2-醇-1-酮和取代的3-羟基-2(5H)-呋喃酮。这种新的序列涉及到许多新的中间体,包括取代的2-氰基环戊酮,取代的2-氰基-2-羟基环戊酮和2-氰基-2-羟基戊烯-γ-内酯。
  • Phenyl pyrrolidine ether tachykinin receptor antagonists
    申请人:DeVita J. Robert
    公开号:US20070043015A1
    公开(公告)日:2007-02-22
    The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, depression, and anxiety.
    本发明涉及某些苯基吡咯烷醚化合物,其作为神经激肽-1(NK-1)受体拮抗剂和快速激肽,特别是物质P的抑制剂具有用途。本发明还涉及包含这些化合物作为活性成分的制药配方以及这些化合物及其配方在治疗某些疾病,包括呕吐、抑郁和焦虑方面的应用。
  • COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE
    申请人:Merck Sharp & Dohme Corp.
    公开号:EP1937264B1
    公开(公告)日:2011-06-08
查看更多